A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection of<i>Trichomonas vaginalis</i>: Table 1

Badman, Steven G; Causer, Louise; Guy, Rebecca; Tabrizi, Sepehr N.; Francis, Fleur; Donovan, Basil; Whiley, David M.

doi:10.1136/sextrans-2015-052384

Cited by 15 publications

(8 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings further support the use of the Xpert Ò CT/NG test for the detection of CT and NG in also specimens from extra-genital sites such as pharynx and rectum. We could also verify the high sensitivity and specificity of the Xpert Ò TV test, which has been indicated in two previous studies (14,15). However, we also show that several non-TV Trichomonas species, in high concentrations, were also positive in the Xpert Ò TV test.…”

Section: Discussionsupporting

confidence: 83%

WHO laboratory validation of Xpert^® CT/NG and Xpert^® TV on the GeneXpert system verifies high performances

Jacobsson

Boiko²,

Golparian

et al. 2018

APMIS

View full text Add to dashboard Cite

Effective tests for diagnosis of sexually transmitted infections ( STI s), used point of care to inform treatment and management decisions, are urgently needed. We evaluated the analytical sensitivity and specificity of the Xpert ® CT / NG and Xpert ® TV tests, examining 339 samples spiked with phenotypically and/or genetically diverse strains of Neisseria gonorrhoeae , Chlamydia trachomatis , and Trichomonas vaginalis , and other related species that may cross‐react. The APTIMA Combo 2 test and APTIMA TV test were used as reference tests. The analytical sensitivity for all three agents in the Xpert ® CT / NG and Xpert ® TV tests was ≤10 2 genome equivalents/reaction. The analytical specificity of both tests was high. False‐positive results were identified in the Xpert ® TV test when challenging with high concentrations of Trichomonas tenax , Trichomonas gallinae, Trichomonas stableri , and Trichomonas aotus . However, the clinical relevance of these cross‐reactions can likely be neglected, because these species have not been identified in urogenital samples from humans. In conclusion, the analytical sensitivity and specificity of the user‐friendly Xpert ® CT / NG and Xpert ® TV tests on the GeneXpert system were high. The results support the use of specimens from also extra‐genital sites, for example, pharynx and rectum. However, appropriate clinical validations are additionally required.

show abstract

Section: Discussionsupporting

confidence: 83%

WHO laboratory validation of Xpert^® CT/NG and Xpert^® TV on the GeneXpert system verifies high performances

Jacobsson

Boiko²,

Golparian

et al. 2018

APMIS

View full text Add to dashboard Cite

show abstract

“…16–18 Nucleic acid amplification tests with high sensitivity (>90%) and high specificity (>90%) 16 are now available as rapid tests that can be implemented in programs suitable for point of care testing for chlamydia, gonorrhea and trichomoniasis. 19,20 There is an urgent need for validation of accurate easy to use point of care tests in low resource settings that will result in more timely targeted treatment and earlier partner management. 21 Our data strongly support a recommendation to transition from syndromic management to targeted annual and repeat testing for STIs among high-risk young women living in HIV endemic communities.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003)

Chirenje¹,

Gundacker²,

Richardson³

et al. 2017

Sexual Trans Dis

View full text Add to dashboard Cite

Background In sub-Saharan Africa, there are limited data on the incidence of sexually transmitted infections (STIs) among women, largely because routine screening for asymptomatic infection is not performed. We conducted a secondary analysis to measure STI incidence rates and determine risk factors for new STI acquisition among women enrolled in the VOICE trial. Methods We analyzed data from 4843 women screened for chlamydia, gonorrhoea, syphilis, and trichomonas infection at baseline, annually, at interim visits when clinically indicated and at their study termination visit. Risk reduction counseling and condoms were provided throughout the trial. Results Twenty percent of evaluable participants had one or more curable STIs at baseline. Over 5660 person-years at risk (PYAR) of observation, incidence rates were 13.8% (95% confidence interval [CI], 12.7–14.8) PYAR for chlamydia, 3.5% (95% CI, 3.0–4.1) PYAR gonorrhea, 0.1% (95% CI, 0.6–1.1) PYAR syphilis, and 6.6% (95% CI, 5.8–7.2) PYAR trichomoniasis. South African sites had the highest incidence of chlamydia. The Uganda site had the highest incidence of gonorrhoea and syphilis, and Zimbabwe the lowest incidence overall. The majority of these cases were diagnosed at a routine scheduled testing visit. In multivariate analysis, positive baseline STI, younger than 25 years, being unmarried, and some alcohol consumption were associated with acquiring a new STI. Conclusions We observed high rates of STIs during follow up among women in the VOICE study. Women living in human immunodeficiency virus endemic countries should be screened for common STIs.

show abstract

“…Xpert provides 90-minute detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae and 59 minutes for Trichomonas vaginalis . Performance evaluations have found that the sensitivity for the Xpert Chlamydia trachomatis test in females using a vaginal sample is 98.7% (95% CI: 93.1–100), Neisseria gonorrhoeae is 100.0% (95% CI: 87.3–100), and Trichomonas vaginalis is 100% (95% CI: 75.3–100.0) [ 26 – 28 ]. The specificity for the Xpert Chlamydia trachomatis test in females using a vaginal sample is 99.4% (95% CI: 98.9–99.7), Neisseria gonorrhoeae is 99.9% (95% CI: 99.6–100), and Trichomonas vaginalis is 100% (95% CI: 78.1–100.0) [ 26 – 28 ].…”

Section: Methodsmentioning

confidence: 99%

Acceptability and Feasibility of Sexually Transmitted Infection Testing and Treatment among Pregnant Women in Gaborone, Botswana, 2015

Wynn

Ramogola‐Masire

Gaolebale³

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Introduction. Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) are curable sexually transmitted infections (STIs) that can cause adverse maternal and birth outcomes. Most countries do not conduct routine testing during antenatal care. We present data on the acceptability and feasibility of testing and treating pregnant women for STIs in an antenatal clinic in Gaborone, Botswana. Materials and Methods. We offered CT, NG, and TV testing using self-collected vaginal swabs to eligible pregnant women. Participants received same-day test results. Those who tested positive were given treatment. Results. Among the 225 women who were eligible and recruited, 200 (89%) agreed to participate. The median age of our study sample was 30 years; most were unmarried (77%), with a median gestational age of 27 weeks and a 23% HIV prevalence. All participants received their results with at least 72% (n = 143) on the same day. Thirty participants (15%) tested positive for an STI, all were treated, and 24 (80%) were treated on the same day. Conclusion. The acceptability of STI testing was high, and the intervention was feasible. This study provides support for continued research into STI prevalence, cost-effectiveness, and the association of STIs with adverse maternal and infant outcomes.

show abstract

A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection ofTrichomonas vaginalis: Table 1

Cited by 15 publications

References 7 publications

WHO laboratory validation of Xpert^® CT/NG and Xpert^® TV on the GeneXpert system verifies high performances

WHO laboratory validation of Xpert^® CT/NG and Xpert^® TV on the GeneXpert system verifies high performances

Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003)

Acceptability and Feasibility of Sexually Transmitted Infection Testing and Treatment among Pregnant Women in Gaborone, Botswana, 2015

Contact Info

Product

Resources

About

A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection ofTrichomonas vaginalis: Table 1

Cited by 15 publications

References 7 publications

WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the GeneXpert system verifies high performances

WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the GeneXpert system verifies high performances

Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003)

Acceptability and Feasibility of Sexually Transmitted Infection Testing and Treatment among Pregnant Women in Gaborone, Botswana, 2015

Contact Info

Product

Resources

About

WHO laboratory validation of Xpert^® CT/NG and Xpert^® TV on the GeneXpert system verifies high performances

WHO laboratory validation of Xpert^® CT/NG and Xpert^® TV on the GeneXpert system verifies high performances